Katholieke Universiteit Leuven, Leuven, Belgium

Group Description

Brief description of legal entity
The partners at the University of Leuven (KUL) are already collaborating within a tracer/contrast agents development and preclinical imaging consortium (IMIR, In vivo Molecular Imaging Research Leuven) and a neurodegenerative consortium (LIND, Leuven Research Institute for Neurodegenerative Disorders). Therefore, the KUL group has also strong inter-faculty and interdisciplinary links between basic researchers and medical imaging scientist, involving faculties of medicine, pharmacy and engineering (image processing).

Main tasks
IMIR and LIND focus their scientific work on development of new molecular imaging probes and multimodal studies of major diseases. Neurodegeneration has strong translational links ranging from genetics, neurobiology, neurophysiology, clinical neuroscience and imaging across subdisciplines. There is a structural basis to integrate preclinical models and clinical applications (both in academic research as well as extended collaborations with (radio)pharmaceutical multinational industry partners).

Participation in INMiND: WP3 / WP4 / WP5 / WP6 / WP7 / WP8.

Previous experience relevant to INMiND tasks

Multi-modal imaging of experimental models of neurodegeneration (AD, PD, HD, ALS) by μPET, μMRI, μCT, ultrasound and optical imaging, and of patients by SPECT/CT, PET/CT; radiotracer development; development of animal models (eg. LV/AAV Parkinson’s disease rodent model); development of clinical techniques for quantification, early and differential diagnosis. Expertise in intra-university consortia (MoSAIC molecular small imaging centre Leuven), as well as LIND. International active participation in FP6 NoE DiMI (www.dimi.eu), multiple interactions with pharmaceutical industry also on specific targets in neurodegeneration. Prof. Dr. Van Laere has headed the EANM NeuroImaging committee during the past years, organising neuroimaging symposia at various international congresses. KUL has established a broad and coordinated research programme in neurodegeneration and inflammation allowing multi-modal molecular imaging studies (PET, MRI, optical) in animal models and patients employing e.g. [11C]NE40 (CB2 ligand), in addition to standard contrast agents and radiotracers. KUL has a centralised small animal molecular imaging facility offering all major molecular imaging modalities combined in a biohazard class II lab, and has extensive experience with PET studies for early phase clinical research including first in man studies with PET tracers.

University of Leuven
INMiND Office
European Institute for Molecular Imaging (EIMI) Waldeyerstr. 15
· 48149 Münster
Tel: +49 251 83 49300 · Fax: +49 251 83 49313